Pioneering the science of time

Every day, we seek to transform science into more time for life. Time to be with families, time to be productive community members, time to feel the small moments of joy that shape our lives.

Our company

Photo: K.G., living with systemic mastocytosis

The urgency of now

We are constantly on the move, relentless in our determination to accelerate development of new therapies, expedite clinical trials and quickly bring approved medicines to patients worldwide.

Our pipeline

Photo: C.N., living with systemic mastocytosis

Precision that moves

We help patients stay one step ahead with therapies that adapt to disease evolution. This includes solving for treatment resistance and intractable sites of progression, as well as pioneering innovative combinations to prolong benefit.

Our platform

Diversity sparks innovation

Our diverse team is passionate about science and thrives on working together to achieve the impossible. We use every opportunity to think differently, make bold decisions and pioneer novel solutions.

Our opportunities

Recent News

More News

Events and presentations

More events and presentations

Our commitment to patients

At Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve the lives of people with genomically defined diseases.

read on

Clinical programs

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Avapritinib

development programs

  • Advanced gastrointestinal stromal tumors
  • Advanced systemic mastocytosis
  • Indolent systemic mastocytosis
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Elenestinib (BLU-263)

development program

  • Indolent systemic mastocytosis
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

BLU-222

Development programs

  • CDK2-vulnerable cancers, including:
    • Hormone receptor-positive, HER2-negative metastatic breast cancer
    • Advanced cyclin E aberrant ovarian, endometrial and other cancers
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Fidrisertib (Blu-782, IPN60130)

development program

Learn more

Fidrisertib is an investigational ALK2 inhibitor being developed for the treatment of FOP. In October 2019, we entered into an exclusive, worldwide license agreement with Clementia Pharmaceuticals, a subsidiary of Ipsen, to develop and commercialize fidrisertib.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Meet the Blue Crew

Meet the Blue Crew

Brittany Carroll, Vice President, Therapy Area Lead

I lead a team tasked with guiding our long-term strategy for mast cell diseases. We work across all functions, from research to development to commercial, to map out strategic plans for our therapeutics and targets while ensuring that cross-functional teams are set up to best support the patients we serve.

Read on

We aspire to pioneer multiple new scientific advances in disease biology and the design of precision therapies. To learn more about our scientific leadership and perspectives, visit Our Blueprint.

read on

Unleashing the potential of kinase therapies

Our scientific presentations and publications

Seeking to deliver transformative medicines

Download Our latest corporate presentation
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”
Kate Haviland, Chief Executive Officer
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”
Kate Haviland, Chief Executive Officer

Dare to be different

We believe diversity is the key to unlocking our full potential. We push boundaries and take well-calculated risks, committing courageously and wholeheartedly to what we believe in.

read on